Drug active against New Delhi beta lactamase producing strain:
**Core Concept**
The New Delhi beta-lactamase (NDM-1) is an enzyme that confers carbapenem resistance in Gram-negative bacteria, making it a significant public health concern. This enzyme is capable of hydrolyzing most beta-lactam antibiotics, including carbapenems, which are typically reserved for infections caused by multidrug-resistant organisms.
**Why the Correct Answer is Right**
The correct answer is a drug that is stable against hydrolysis by NDM-1. This is because it has a modified beta-lactam ring structure that is resistant to cleavage by the enzyme. The active site of NDM-1 is highly specific for the beta-lactam ring, and modifications to this ring can prevent hydrolysis. The correct answer is a carbapenem antibiotic that has been engineered to resist hydrolysis by NDM-1.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is a different carbapenem antibiotic that is susceptible to hydrolysis by NDM-1.
**Option B:** This option is incorrect because it is a different class of antibiotic that is not a carbapenem and is not stable against NDM-1.
**Option C:** This option is incorrect because it is a beta-lactamase inhibitor that can inhibit the activity of NDM-1, but it is not a carbapenem antibiotic itself.
**Clinical Pearl / High-Yield Fact**
It's essential to recognize that NDM-1-producing organisms are often multidrug-resistant and may require the use of carbapenems as a last resort. The development of carbapenem-resistant Enterobacteriaceae (CRE) has become a significant public health concern.
**Correct Answer:** C.